The European Medicines Agency (EMA) has granted PRIME eligibility to two advanced therapy medicinal products: an adeno-associated virus serotype 8 vector carrying the human AIPL1 gene for the treatment of AIPL1-associated inherited retinal dystrophy, and an adeno-associated viral vector serotype 2 encoding glial cell line-derived neurotrophic factor for the treatment of Parkinson's disease. The decisions were adopted at the Committee for Medicinal Products for Human Use (CHMP) meeting of 20-23 July 2026, as detailed in a document published by the Agency on 6 August 2026. Both products were supported by non-clinical and exploratory clinical data, and both applicants are classified as 'other' (not SME or academic sponsors). In total, the CHMP reviewed seven recommendations for PRIME eligibility during the July meeting, granting two and denying five. The PRIME scheme, launched by EMA in 2016, aims to enhance support for medicines that target unmet medical needs, offering accelerated assessment and enhanced dialogue with developers. The two granted products address serious conditions with limited treatment options, potentially bringing significant benefits to patients with AIPL1-associated inherited retinal dystrophy and Parkinson's disease. However, the denial of five other applications underscores the scheme's selectivity, as EMA requires compelling evidence of therapeutic potential. For developers, PRIME eligibility can reduce time to market, but the rigorous criteria may exclude promising candidates, potentially delaying patient access. The outcomes also reflect a balance between fostering innovation in gene therapy and ensuring that resources are focused on products with the strongest evidence, impacting both small biotech firms and larger pharmaceutical companies seeking regulatory support.
Source📄 Open document ↗